Colon cancer (adjuvant) - capecitabine and oxaliplatin: review decision - June 2011 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 59 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 445 KB)
-
-
Appendix A: decision paper considered by the Institute's Guidance Executive
-
Appendix A: decision paper considered by the Institute's Guidance Executive (PDF 94 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 128 KB)
Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination)
Consultee and commentator comments on Appraisal Consultation Document
-
Consultee and commentator comments on Appraisal Consultation Document
-
Consultee and commentator comments on Appraisal Consultation Document (PDF 100 KB)
Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin
Overview
-
Overview
-
Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report
-
Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report
-
Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report (PDF 2.11 MB)
Response to Consultee Comments
-
Response to Consultee Comments
-
Consultee and commentator comment on the assessment report
-
Consultee and commentator comment on the assessment report
-
Colon Cancer Concern
-
-
Institute for Cancer Research
-
-
NHS QIS
-
-
Royal College of Nursing
-
-
Royal College of Physicians
-
Non-manufacturer submissions
-
Non-manufacturer submissions
-
British Oncology Pharmacy Association (1)
-
-
British Oncology Pharmacy Association (2)
-
-
CancerBACUP
-
-
Cancer Concern
-
-
Joint submission - Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology
-
-
Royal College of Nursing
-
Manufacturer submissions
-
Manufacturer submissions
-
Roche
-
-
Roche executive summary
-
-
Sanofi Aventis
-
-
Sanofi Aventis updated submission - new evidence
-
Sanofi Aventis updated submission - new evidence (PDF 161 KB)
-
Sanofi Aventis executive summary
-
Expert written personal statements
-
Expert written personal statements
-
Craven
-
-
Levine
-
-
Marks
-
-
Sharma
-
Final protocol
-
Final protocol
-
Final scope
-
Final scope
-
Summary of consultee comments on the draft scope
-
Summary of consultee comments on the draft scope
-
Summary of consultee comments on the draft scope (PDF 44 KB)
Summary of consultee and commentator comments on provisional matrix
-
Summary of consultee and commentator comments on provisional matrix
-
Summary of consultee and commentator comments on provisional matrix (PDF 22 KB)
Archive: draft scope
-
Archive: draft scope
-
Archive: provisional matrix of consultees and commentators
-
Archive: provisional matrix of consultees and commentators
-
Archive: provisional matrix of consultees and commentators (PDF 29 KB)